檢索結果 - Mark-David Levin

Refine Results
  1. 1
    Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases

    Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases 由 Arjen Yousefi, Mark‐David Levin, Jan J. Cornelissen, Peter E. Westerweel

    出版 2025
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia

    New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia 由 Peter E. Westerweel, Peter te Boekhorst, Mark‐David Levin, Jan J. Cornelissen

    出版 2019
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature

    The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature 由 Hánah N. Rier, Agnes Jager, Stefan Sleijfer, Andrea B. Maier, Mark‐David Levin

    出版 2016
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  4. 4
    Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy

    Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy 由 Hánah N. Rier, Agnes Jager, Stefan Sleijfer, Joost van Rosmalen, Marc C. J. M. Kock, Mark‐David Levin

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice

    Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice 由 Nathalie I. Bouwer, Agnes Jager, Crista Liesting, Marcel J.M. Kofflard, Jasper J. Brugts, Jos Kitzen, Eric Boersma, Mark‐David Levin

    出版 2020
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients

    Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients 由 Paul J. Hengeveld, Joyce Schilperoord‐Vermeulen, P. Martijn Kolijn, Julie Dubois, Peter E. Westerweel, Sabina Kersting, Arnon P. Kater, Mark‐David Levin, Anton W. Langerak

    出版 2025
    獲取全文
    Carta
    加到收藏夾
    Saved in:
  7. 7
    Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019

    Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019 由 Lina van der Straten, Mark‐David Levin, Manette A. W. Dinnessen, Otto Visser, Eduardus F. M. Posthuma, Jeanette K. Doorduijn, Anton W. Langerak, Arnon P. Kater, Avinash G. Dinmohamed

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study

    Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study 由 Marinus H. J. van Oers, Kazimierz Kuliczkowski, Lukáš Smolej, Mario Petrini, Fritz Offner, Sebastian Grosicki, Mark-David Levin, Ira Gupta, Jennifer L. Phillips, Vanessa C. Williams, Stephanie Manson, Steen Lisby, Christian H. Geisler

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia

    A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia 由 Iris de Weerdt, Roeland Lameris, Jurjen M. Ruben, Renate de Boer, Jan Kloosterman, Lisa A. King, Mark‐David Levin, Paul W.H.I. Parren, Tanja D. de Gruijl, Arnon P. Kater, Hans van Vliet

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Efficacy and safety of daratumumab combined with all-<i>trans</i>retinoic acid in relapsed/refractory multiple myeloma

    Efficacy and safety of daratumumab combined with all-<i>trans</i>retinoic acid in relapsed/refractory multiple myeloma 由 Kristine A. Frerichs, Monique C. Minnema, Mark‐David Levin, Annemiek Broijl, Gerard M.J. Bos, Marie José Kersten, Tuna Mutis, Christie P.M. Verkleij, Inger S. Nijhof, Patricia W. C. Maas-Bosman, Saskia K. Klein, Sonja Zweegman, Pieter Sonneveld, Niels W.C.J. van de Donk

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial 由 Pieter Sonneveld, Asher Chanan‐Khan, Katja Weisel, Ajay K. Nooka, Tamás Masszi, Meral Beksaç, Ivan Špıčka, Vânia Hungria, Markus Munder, María‐Victoria Mateos, Tomer M. Mark, Mark‐David Levin, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Andrew Spencer

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

    Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (... 由 Philippe Moreau, Sonja Zweegman, Aurore Perrot, Cyrille Hulin, Denis Caillot, Thierry Façon, Xavier Leleu, Karim Belhadj, Lionel Karlin, Lotfi Benboubker, Mark‐David Levin, Monique C. Minnema, Bastien Jamet, Caroline Bodet‐Milin, Pieter Sonneveld, Jérôme Lambert, Lixia Pei, Carla de Boer, Jessica Vermeulen, Tobias Kampfenkel, Françoise Kraeber‐Bodéré

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation

    Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation 由 Paul G. Kemps, Konnie M. Hebeda, Steven T. Pals, Robert M. Verdijk, King H. Lam, Annette H. Bruggink, Heleen S de Lil, Bart Ruiterkamp, Koen de Heer, Jan AM van Laar, Peter J.M. Valk, Pim Mutsaers, Mark‐David Levin, Pancras C.W. Hogendoorn, Astrid G. S. van Halteren

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy

    Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy 由 Jaco A. C. van Bruggen, Anne W. J. Martens, Joseph A. Fraietta, Tom Hofland, Sanne H. Tonino, Eric Eldering, Mark‐David Levin, Peter J. Siska, Sanne Endstra, Jeffrey C. Rathmell, Carl H. June, David L. Porter, J. Joseph Melenhorst, Arnon P. Kater, Gerritje J. W. van der Windt

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    COVID-19 vaccination in patients with immune thrombocytopenia

    COVID-19 vaccination in patients with immune thrombocytopenia 由 Chantal Visser, Maurice Swinkels, Erik van Werkhoven, F. Nanne Croles, H. S. Noordzij-Nooteboom, Matthijs Eefting, Suzanne Last-Koopmans, Cecile Idink, Peter E. Westerweel, Bart Santbergen, Pieter A. Jobse, Fazil Baboe, Peter te Boekhorst, Frank W.G. Leebeek, Mark‐David Levin, Marieke J. H. A. Kruip, A.J. Gerard Jansen

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

    Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment 由 Iris de Weerdt, Tom Hofland, Renate de Boer, Johan A. Dobber, Julie Dubois, Denise van Nieuwenhuize, Mehrdad Mobasher, Fransien de Boer, Mels Hoogendoorn, Gerjo A. Velders, Marjolein van der Klift, Ester B. M. Remmerswaal, Fréderike J. Bemelman, Carsten Utoft Niemann, Sabina Kersting, Mark‐David Levin, Eric Eldering, Sanne H. Tonino, Arnon P. Kater

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

    First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study 由 Carol Moreno, Talha Munir, Carolyn Owen, George Follows, Jose-Angel Hernandez Rivas, Ohad Benjamini, Ann Janssens, Mark‐David Levin, Tadeusz Robak, Martin Šimkovič, Sergey Voloshin, Vladimir Vorobyev, Münci Yağcı, Loïc Ysebaert, Qianya Qi, Emma A. Elliott Smith, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P. Kater

    出版 2023
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib

    Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib 由 Iris de Weerdt, Tom Hofland, Roeland Lameris, Sanne Endstra, Aldo Jongejan, Perry D. Moerland, Renée C.G. de Bruin, Ester B. M. Remmerswaal, Ineke J. M. ten Berge, Nora Liu, Mario van der Stelt, Laura M. Faber, Mark‐David Levin, Eric Eldering, Sanne H. Tonino, Tanja D. de Gruijl, Hans van Vliet, Arnon P. Kater

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

    Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analys... 由 Arnon P. Kater, Mark‐David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, G.J. Veldhuis, Rogier Mous, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Johan A. Dobber, Christian Bjørn Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Christian Brieghel, Mattias Mattsson, Mar Bellido, Hoa Tran, Kazem Nasserinejad, Carsten Utoft Niemann

    出版 2022
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

    Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study 由 Talha Munir, Carol Moreno, Carolyn Owen, George Follows, Ohad Benjamini, Ann Janssens, Mark‐David Levin, Anders Österborg, Tadeusz Robak, Martin Šimkovič, Don A. Stevens, Sergey Voloshin, Vladimir Vorobyev, Münci Yağcı, Loïc Ysebaert, Keqin Qi, Qianya Qi, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P. Kater

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: